Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Cabaletta Bio Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
CABA
Nasdaq
8731
https://www.cabalettabio.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Cabaletta Bio Inc
Cabaletta Bio Inc (CABA) Earnings: Aligns with EPS Projections, Forecasts Extended Cash Runway
- Mar 23rd, 2024 9:31 am
Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Mar 21st, 2024 11:00 am
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis
- Mar 20th, 2024 11:00 am
Jim Cramer’s 10 Latest Stock Picks This Week
- Mar 8th, 2024 1:50 pm
Several Factors Led to the Outperformance of Cabaletta Bio (CABA) in Q4
- Feb 27th, 2024 3:11 pm
Cabaletta Bio to Participate in Upcoming Investor Conferences in March
- Feb 27th, 2024 1:00 pm
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis
- Feb 1st, 2024 9:30 pm
Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
- Jan 31st, 2024 1:00 pm
Are Investors Undervaluing Cabaletta Bio, Inc. (NASDAQ:CABA) By 47%?
- Jan 9th, 2024 11:27 am
Cabaletta Bio Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis
- Jan 8th, 2024 12:00 pm
Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Jan 2nd, 2024 1:00 pm
Cabaletta Bio Stock (NASDAQ:CABA): Analysts Expect More Gains Despite Massive Rally
- Dec 19th, 2023 1:49 am
Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference
- Nov 28th, 2023 9:30 pm
Cabaletta Bio Inc (CABA) Reports Q3 2023 Financial Results and Business Progress
- Nov 9th, 2023 1:10 pm
Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update
- Nov 9th, 2023 12:00 pm
Cellares and Cabaletta Bio Partner to Evaluate Automated Manufacturing for CABA-201, Cabaletta’s CD19-CAR T Cell Therapy on Cellares’ Cell Shuttle Platform
- Nov 6th, 2023 1:15 pm
Cabaletta Bio Receives FDA Clearance of CABA-201 IND Application for Treatment of Generalized Myasthenia Gravis
- Nov 6th, 2023 12:00 pm
Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in November
- Oct 30th, 2023 12:00 pm
Are Medical Stocks Lagging Cabaletta Bio (CABA) This Year?
- Oct 9th, 2023 1:40 pm
Pleasing Signs As A Number Of Insiders Buy Cabaletta Bio Stock
- Oct 2nd, 2023 6:12 pm
Scroll